CYBN - Cybin Revenue Growth YoY (Last 12 Months)

Brandmark of Cybin (CYBN)

Cybin Inc. (CYBN) is developing psychedelics within the North American legal framework, which eliminates sanction threats. The relative change in trailing twelve-month revenue compared to the same period last year demonstrates scaling dynamics, where 0.00 represents the latest metric reading. While prospects are tied to establishing a revolutionary psychiatric standard, the lack of commercial products and the costs associated with FDA trials create significant risks for capital.

Cybin Corp (CYBN) Sales Growth YoY (TTM): for the period 02/11/2024 - 01/05/2026

Summary analytical data breakdowns for cybin.com (CYBN)

- market value and analyst target forecast:
Fundamental company valuation:cybin.com
Signature product of Cybin Inc.

Cybin Inc. specializes in developing innovative psychedelic drugs for depression therapy using artificial intelligence. By analyzing the trailing twelve-month (TTM) sales growth rate, an investor assesses revenue dynamics over the last twelve months relative to the previous year, which helps identify the sustainability of business expansion or the risk of capital stagnation during the development of new drug formulas.